α-Blockers for the treatment of chronic prostatitis/chronic pelvic pain syndrome: An update on current clinical evidence - Abstract

The pathogenesis of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is multifactorial, making its treatment difficult.

Multimodal therapy including α-adrenergic antagonists (α-blockers), anti-inflammatory agents, and other pain treatments may provide optimal management for CP/CPPS. Although α-blockers are the most prescribed drugs for patients with CP/CPPS, not all studies support their efficacy. A recent meta-analysis of small trials suggested that treatment with α-blockers, possibly in combination with antibacterial agents, is efficacious in relieving symptoms. Third-generation α1A blockers (silodosin, tamsulosin) may provide efficacy as well as reduced cardiovascular side effects. Future research should aim to identify potential biomarkers associated with treatment response.

Written by:
Nickel JC, Touma N.   Are you the author?
Kingston General Hospital, Kingston, Ontario, Canada.

Reference: Rev Urol. 2012;14(3-4):56-64.


PubMed Abstract
PMID: 23526487

UroToday.com Prostatitis Section

 

 

email news signup